Celgene's Revlimid Thrives As First-Line Multiple Myeloma Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Spurred by backing of physician opinion leaders, sales grow quickly ahead of first-line filing, which is expected in the second half of 2010.
You may also be interested in...
Market Snapshot: Multiple Myeloma Drugs Promise To Live Up To Hype
Spurred by the introduction of new and highly effective drugs that have vastly improved survival rates, the fast-moving myeloma market is becoming a very attractive sector in oncology
Market Snapshot: Multiple Myeloma Drugs Promise To Live Up To Hype
Spurred by the introduction of new and highly effective drugs that have vastly improved survival rates, the fast-moving myeloma market is becoming a very attractive sector in oncology
ASH Preview: Researchers Chase Winning Combination In Frontline Myeloma
At this year's American Society of Hematology meeting, scientists will present data suggesting a cocktail of Revlimid, Velcade and dexamethasone could emerge as the backbone of frontline therapy for multiple myeloma